Meeting
2019 ASCO Annual Meeting
Single-arm, phase II study of pyrotinib in advanced non-small cell lung cancer (NSCLC) patients with HER2 exon 20 mutation.
Authors
Guanghui Gao
Shanghai Pulmonary Hospital, Shanghai, China
Guanghui Gao , Xingya Li , Qiming Wang , Yiping Zhang , Jianhua Chen , Yongqian Shu , Yanping Hu , Yun Fan , Jian Fang , Gongyan Chen , Jun Zhao , Jianxing He , Fengying Wu , Jianjun Zou , Xiaoyu Zhu , Caicun Zhou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02834936
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9089)
DOI
10.1200/JCO.2019.37.15_suppl.9089
Abstract #
9089
Poster Bd #
412
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Amivantamab and lazertinib in treatment-naïve EGFR-mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS.
First Author: Se-Hoon Lee
Poster
2022 ASCO Annual Meeting
A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer.
First Author: Yuangyuan Zhao
Poster
2021 ASCO Annual Meeting
Interim results of a phase II single arm trial combining afatinib with cetuximab in patients with EGFRex20ins positive NSCLC.
First Author: Bianca van Veggel
Poster
2020 ASCO Virtual Scientific Program
Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non–small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.
First Author: Harry J.M. Groen